I-Mab
IMAB
Cena:
$ 2.88
-0.02 (-0.69%)
Valuace
70
Růst
53
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
I-MAB (NASDAQ: IMAB) TRANSITIONS TO NOVABRIDGE BIOSCIENCES (NASDAQ: NBP) WITH TRADING EFFECTIVE OCTOBER 30, 2025 NEW BRAND AND LOGO TO REFLECT STRATEGIC TRANSFORMATION TO A GLOBAL BIOTECH PLATFORM
29-10-2025
NEW CORPORATE BRAND REFLECTS STRATEGIC TRANSFORMATION TO A GLOBAL BIOTECH PLATFORM ACCELERATING ACCE...
Více zde
INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF I-MAB - IMAB
28-10-2025
NEW YORK , OCT. 28, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde
INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF I-MAB - IMAB
23-10-2025
NEW YORK , OCT. 23, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde
I-MAB TO PRESENT POSITIVE UPDATED GIVASTOMIG MONOTHERAPY DATA AT 2025 AACR-NCI-EORTC MOLECULAR TARGETS AND CANCER THERAPEUTICS CONFERENCE ON OCTOBER 23, 2025
22-10-2025
ROCKVILLE, MD., OCT. 22, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ: IMAB) (I-MAB OR THE COMPANY), IS A ...
Více zde
I-MAB ANNOUNCES INTENTION TO UNDERTAKE STRATEGIC TRANSFORMATION TO GLOBAL BIOTECH PLATFORM, TO PURSUE HONG KONG IPO, AND REBRAND AS NOVABRIDGE BIOSCIENCES
16-10-2025
ROCKVILLE, MD., OCT. 16, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ: IMAB) (I-MAB OR THE COMPANY), A GLO...
Více zde
I-MAB TO PRESENT SHORT-TALK ON UPDATED GIVASTOMIG MONOTHERAPY DATA AT THE 2025 AACR-NCI-EORTC MOLECULAR TARGETS AND CANCER THERAPEUTICS CONFERENCE
14-10-2025
THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS TO BE HELD ...
Více zde
I-MAB ANNOUNCES THE APPOINTMENT OF SEASONED BIOTECH EXECUTIVES TO THE BOARD OF DIRECTORS AND THE SCIENTIFIC ADVISORY BOARD, AND THE FORMATION OF A RESEARCH AND DEVELOPMENT COMMITTEE
25-08-2025
ROCKVILLE, MD., AUG. 25, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ:IMAB) (THE COMPANY), A U.S.-BASED, G...
Více zde
I-MAB TO PARTICIPATE IN SEPTEMBER INVESTOR CONFERENCES
21-08-2025
ROCKVILLE, MD., AUG. 21, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ: IMAB) (THE “COMPANY”), A U.S.-B...
Více zde
EVEREST MEDICINES EXPANDS STRATEGIC INVESTMENT IN I-MAB
01-08-2025
- EVEREST WILL INVEST US$30.9 MILLION (EQUIVALENT TO APPROXIMATELY HK$242.6 MILLION) IN CASH IN I-MA...
Více zde
I-MAB ANNOUNCES PRICING OF $65 MILLION UNDERWRITTEN OFFERING OF AMERICAN DEPOSITARY SHARES
01-08-2025
ROCKVILLE, MD., AUG. 01, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ: IMAB) (THE COMPANY), A U.S.-BASED, ...
Více zde
I-MAB STRENGTHENS GIVASTOMIG INTELLECTUAL PROPERTY PORTFOLIO THROUGH ACQUISITION OF BRIDGE HEALTH
17-07-2025
ROCKVILLE, MD., JULY 17, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ: IMAB) (THE COMPANY), A U.S.-BASED, ...
Více zde
I-MAB PRESENTS POSITIVE GIVASTOMIG PHASE 1B DOSE ESCALATION DATA IN COMBINATION WITH IMMUNOCHEMOTHERAPY IN PATIENTS WITH 1L GASTRIC CANCERS AT ESMO GI 2025
02-07-2025
DATA SHOW CONFIRMED ORR OF 83% (10/12) AT DOSES SELECTED FOR ONGOING EXPANSION STUDY MEDIAN FOLLOW-U...
Více zde
I-MAB ANNOUNCES PUBLICATION OF GIVASTOMIG MONOTHERAPY DATA IN CLINICAL CANCER RESEARCH
30-06-2025
MONOTHERAPY EFFICACY AND SAFETY PROFILE PROVIDED BACKBONE FOR CLINICAL DEVELOPMENT STRATEGY IN 1L ...
Více zde
I-MAB HIGHLIGHTS POSITIVE GIVASTOMIG PHASE 1B DOSE ESCALATION DATA IN COMBINATION WITH IMMUNOCHEMOTHERAPY IN PATIENTS WITH 1L GASTRIC CANCERS AT ESMO GI 2025
26-06-2025
71% OBJECTIVE RESPONSE RATE (ORR) (12/17) PER RECIST V1.1, WITH A FAVORABLE SAFETY PROFILE 83% ORR (...
Více zde
I-MAB TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
20-05-2025
ROCKVILLE, MD., MAY 20, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ: IMAB) (THE “COMPANY”), A U.S.-BA...
Více zde
I-MAB ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY NOTICE REGARDING MINIMUM BID PRICE REQUIREMENT
21-03-2025
ROCKVILLE, MD., MARCH 21, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ: IMAB) (“I-MAB” OR THE “COMPA...
Více zde
I-MAB ANNOUNCES ACCELERATED GIVASTOMIG PHASE 1B STUDY PROGRESS
07-03-2025
ROCKVILLE, MD., MARCH 07, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ: IMAB) (THE “COMPANY”), A U.S.-...
Více zde
I-MAB TO PARTICIPATE IN LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE
18-02-2025
ROCKVILLE, MD., FEB. 18, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ: IMAB) (THE “COMPANY”), A US-BAS...
Více zde
I-MAB TO PRESENT AT OPPENHEIMER'S 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE
04-02-2025
ROCKVILLE, MD., FEB. 04, 2025 (GLOBE NEWSWIRE) -- I-MAB (NASDAQ: IMAB) (THE COMPANY), A U.S.-BASED, ...
Více zde
I-MAB ANNOUNCES OPEN MARKET PURCHASES OF COMPANY AMERICAN DEPOSITARY SHARES BY BOARD MEMBER
08-01-2025
CHAIRMAN OF THE BOARD, WEI FU, INFORMED THE COMPANY OF HIS INTENT TO PURCHASE UP TO $2,000,000 OF TH...
Více zde
I-MAB ANNOUNCES PORTFOLIO PRIORITIZATION OF GIVASTOMIG (CLDN18.2 X 4-1BB BISPECIFIC ANTIBODY) AS LEAD CLINICAL PROGRAM
06-01-2025
GIVASTOMIG: A CLAUDIN 18.2 ("CLDN18.2") X 4-1BB BISPECIFIC ANTIBODY, WILL BE THE LEAD CLINICAL PROGR...
Více zde
I-MAB TO PARTICIPATE AT THE PIPER SANDLER HEALTHCARE CONFERENCE
21-11-2024
THE 36TH ANNUAL HEALTHCARE CONFERENCE WILL BE HELD IN NEW YORK, DECEMBER 3-5, 2024 ROCKVILLE, MD. , ...
Více zde
I-MAB REPORTS THIRD QUARTER 2024 RESULTS
14-11-2024
GIVASTOMIG DATA PRESENTED AT ESMO 2024 AND SITC 2024 HIGHLIGHTS ENCOURAGING MONOTHERAPY DATA ON TRAC...
Více zde
I-MAB APPOINTS SEAN FU, PHD, MBA, AS CHIEF EXECUTIVE OFFICER
06-11-2024
ROCKVILLE, MD. , NOV. 6, 2024 /PRNEWSWIRE/ -- I-MAB (NASDAQ: IMAB) (THE "COMPANY"), A U.S.-BASED, G...
Více zde
I-MAB TO RELEASE Q3 2024 FINANCIAL RESULTS ON NOVEMBER 14, 2024
31-10-2024
ROCKVILLE, MD. , OCT. 31, 2024 /PRNEWSWIRE/ -- I-MAB (NASDAQ: IMAB) (THE "COMPANY"), A US-BASED, GLO...
Více zde
I-MAB TO PRESENT GIVASTOMIG PHASE 1 OPTIMAL DOSE ESTIMATION DATA AT SITC 2024
30-10-2024
- POSTER TO BE PRESENTED IN A LATE-BREAKING ABSTRACT SESSION AT THE SOCIETY FOR IMMUNOTHERAPY OF ...
Více zde
I-MAB TO PARTICIPATE AT THE TRUIST SECURITIES BIOPHARMA SYMPOSIUM
28-10-2024
ROCKVILLE, MD. , OCT. 28, 2024 /PRNEWSWIRE/ -- I-MAB (NASDAQ: IMAB), A US-BASED, GLOBAL, BIOTECH CO...
Více zde
I-MAB PRESENTS UPDATED PHASE 1 GIVASTOMIG DATA AT ESMO 2024
16-09-2024
EXPANDED PHASE 1 MONOTHERAPY STUDY OF GIVASTOMIG, A CLAUDIN 18.2 X 4-1BB BISPECIFIC ANTIBODY IMMUNOS...
Více zde
I-MAB PRESENTS POSITIVE ULILEDLIMAB PHARMACOKINETICS DATA AT 2024 WORLD CONFERENCE ON LUNG CANCER
10-09-2024
- PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING DATA FROM THREE PHASE 1 STUDIES PROVIDING DOSING ...
Více zde
I-MAB REPORTS 1H 2024 FINANCIAL RESULTS, PIPELINE PROGRESS, AND BUSINESS UPDATES
28-08-2024
COMPLETED DIVESTITURE OF CHINA OPERATIONS ULILEDLIMAB IND CLEARANCE PAVES THE WAY FOR U.S. COMBINATI...
Více zde
Dokumenty nejsou k dispozici
